The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Glutamate hypothesis in schizophrenia
Open accessAbstract
Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an individual’s life and on society. Thus, developing more effective therapeutic interventions is essential. Over the past quarter‐century, an abundance of evidence from pharmacologic challenges, post‐mortem studies, brain imaging, and genetic studies supports the role of glutamatergic dysregulation in the pathophysiology of schizophrenia, and the results of recent randomized clinical trials based on this evidence have yielded promising results. In this article, we review the evidence that alterations in glutamatergic neurotransmission, especially focusing on the N‐methyl‐d‐aspartate receptor (NMDAR) function, may be a critical causative feature of schizophrenia, how this contributes to pathologic circuit function in the brain, and how these insights are revealing whole new avenues for treatment development that could reduce treatment‐resistant symptoms, which account for persistent disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Reactive Astrocytes: Production, Function, and Therapeutic Potential
Liddelow, S. A., & Barres, B. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.006 · Cited by 2,336
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120
The P300 wave of the human event-related potential
Picton, T. W. (1992) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199210000-00002 · Cited by 1,908
De novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
Dementia Praecox oder Gruppe der Schizophrenien
Bleuler, E. (1911) · Cited by 1,429
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
A polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385
Proteomic analysis of NMDA receptor–adhesion protein signaling complexes
Husi, H., Ward, M. A., Choudhary, J. S., Blackstock, W. P., & Grant, S. G. N. (2000) · Nature Neuroscience · doi:10.1038/76615 · Cited by 1,194
Genetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177
d -Serine is an endogenous ligand for the glycine site of the N -methyl- d -aspartate receptor
Mothet, J.-P., Parent, A. T., Wolosker, H., Brady, R. O., Linden, D. J., Ferris, C. D., Rogawski, M. A., & Snyder, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4926 · Cited by 1,137
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Self-citationStengel, E. (1960) · BMJ · doi:10.1136/bmj.1.5178.1031-b · Cited by 987
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.154 · Cited by 844
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
Schell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832
Strong association of de novo copy number mutations with sporadic schizophrenia
Xu, B., Roos, J. L., Levy, S., van Rensburg, E. J., Gogos, J. A., & Karayiorgou, M. (2008) · Nature Genetics · doi:10.1038/ng.162 · Cited by 813
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu170 · Cited by 683
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Carlén, M., Meletis, K., Siegle, J. H., Cardin, J. A., Futai, K., Vierling-Claassen, D., Rühlmann, C., Jones, S. R., Deisseroth, K., Sheng, M., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.31 · Cited by 669
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
Pope, H. G. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310017001 · Cited by 632
Hilker, R., Helenius, D., Fagerlund, B., Skytthe, A., Christensen, K., Werge, T. M., Nordentoft, M., & Glenthøj, B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.017 · Cited by 615
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 583
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
Self-citationThe Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Self-citationThe dopamine hypothesis of schizophrenia: focus on the dopamine receptor
(1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.2.197 · Cited by 556
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L. H., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 471
The presence of free D‐serine in rat brain
Hashimoto, A., Nishikawa, T., Hayashi, T., Fujii, N., Harada, K., Oka, T., & Takahashi, K. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80397-y · Cited by 462
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., Hahn, C.-G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420425 · Cited by 455
Analysis of copy number variations at 15 schizophrenia-associated loci
Rees, E., Walters, J. T. R., Georgieva, L., Isles, A. R., Chambert, K. D., Richards, A. L., Mahoney-Davies, G., Legge, S. E., Moran, J. L., McCarroll, S. A., et al. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.131052 · Cited by 443
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Self-citationKetamine activates psychosis and alters limbic blood flow in schizophrenia
Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · NeuroReport · doi:10.1097/00001756-199504190-00011 · Cited by 434
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411
Self-citationHeresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1141 · Cited by 372
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Endogenous d‐Serine in Rat Brain: N‐Methyl‐d‐Aspartate Receptor‐Related Distribution and Aging
Hashimoto, A., Nishikawa, T., Oka, T., & Takahashi, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03219.x · Cited by 361
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Janssen, P. A., Cj, N., & Schellekens, K. H. L. (1965) · PubMed · Cited by 348
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
Basu, A. C., Tsai, G. E., Ma, C.-L., Ehmsen, J. T., Mustafa, A. K., Han, L., Jiang, Z. I., Benneyworth, M. A., Froimowitz, M. P., Lange, N., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.130 · Cited by 338
Self-citationPhenothiazine Treatment in Acute Schizophrenia: Effectiveness
(1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210028005 · Cited by 334
A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia
BENDIKOV, I., NADRI, C., AMAR, S., PANIZZUTTI, R., DEMIRANDA, J., WOLOSKER, H., & AGAM, G. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323
Disease-relevant autoantibodies in first episode schizophrenia
Zandi, M. S., Irani, S. R., Lang, B., Waters, P., Jones, P. B., McKenna, P., Coles, A. J., Vincent, A., & Lennox, B. R. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5788-9 · Cited by 319
Pinault, D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.006 · Cited by 315
Rowland, L. M., Bustillo, J. R., Mullins, P. G., Jung, R. E., Lenroot, R., Landgraf, E., Barrow, R., Yeo, R., Lauriello, J., & Brooks, W. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.394 · Cited by 304
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., & Ell, P. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001751 · Cited by 278
Tsai, G., & Lin, P.-Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267
Spontaneous Gamma Activity in Schizophrenia
Hirano, Y., Oribe, N., Kanba, S., Onitsuka, T., Nestor, P. G., & Spencer, K. M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2642 · Cited by 261
Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis
Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Chung, J. K., Gerretsen, P., Kim, J., Takeuchi, H., Chakravarty, M. M., Remington, G., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw221 · Cited by 251
Sullivan, J. M., Traynelis, S. F., Chen, H.-S. V., Escobar, W., Heinemann, S. F., & Lipton, S. A. (1994) · Neuron · doi:10.1016/0896-6273(94)90258-5 · Cited by 250
NMDA receptors and schizophrenia
KRISTIANSEN, L., HUERTA, I., BENEYTO, M., & MEADORWOODRUFF, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 246
[Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)].
Delay, J., Deniker, P., & Jm, H. (1952) · PubMed · Cited by 244
Serine racemase is predominantly localized in neurons in mouse brain
Miya, K., Inoue, R., Takata, Y., Abe, M., Natsume, R., Sakimura, K., Hongou, K., Miyawaki, T., & Mori, H. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21822 · Cited by 242
Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt, D. (1987) · PubMed · Cited by 240
Moghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238
Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., Wallace, T. L., Knoflach, F., Dorflinger, E., Wettstein, J. G., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.163 · Cited by 234
Lane, H.-Y., Lin, C.-H., Green, M. F., Hellemann, G., Huang, C.-C., Chen, P.-W., Tun, R., Chang, Y.-C., & Tsai, G. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2159 · Cited by 229
Hakami, T., Jones, N. C., Tolmacheva, E. A., Gaudias, J., Chaumont, J., Salzberg, M., O'Brien, T. J., & Pinault, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006755 · Cited by 228
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
Self-citationAsymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses
Law, A. J., & Deakin, J. F. W. (2001) · Neuroreport · doi:10.1097/00001756-200109170-00043 · Cited by 227
Kristiansen, L. V., Beneyto, M., Haroutunian, V, & Meador-Woodruff, J. H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001844 · Cited by 220
Yamasaki, M., Yamada, K., Furuya, S., Mitoma, J., Hirabayashi, Y., & Watanabe, M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07691.2001 · Cited by 220
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 219
Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217
Self-citationKetamine Modulates Theta and Gamma Oscillations
Lazarewicz, M. T., Ehrlichman, R. S., Maxwell, C. R., Gandal, M. J., Finkel, L. H., & Siegel, S. J. (2010) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2009.21305 · Cited by 209
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Snyder, S. H. (1980) · Nature · doi:10.1038/285355a0 · Cited by 205
Matsuzawa, D., Obata, T., Shirayama, Y., Nonaka, H., Kanazawa, Y., Yoshitome, E., Takanashi, J., Matsuda, T., Shimizu, E., Ikehira, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001944 · Cited by 201
Ventricular Enlargement in Poor-Outcome Schizophrenia
Davis, K. L., Buchsbaum, M. S., Shihabuddin, L., Spiegel-Cohen, J., Metzger, M., Frecska, E., Keefe, R. S., & Powchik, P. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00553-2 · Cited by 200
Adjunctive high-dose glycine in the treatment of schizophrenia
Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A.-M., Bark, N., Park, M., Lindenmayer, J.-P., Suckow, R., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199
Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia
Nishikawa, T., Takashima, M., & Toru, M. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90046-0 · Cited by 196
The Rise and Fall of the d -Serine-Mediated Gliotransmission Hypothesis
Wolosker, H., Balu, D. T., & Coyle, J. T. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.007 · Cited by 195
Self-citationNovel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia
Pocklington, A. J., Rees, E., Walters, J. T. R., Han, J., Kavanagh, D. H., Chambert, K. D., Holmans, P., Moran, J. L., McCarroll, S. A., Kirov, G., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.04.022 · Cited by 193
USE OF RAUWOLFIA SERPENTINA BENTH. IN NEUROPSYCHIATRIC CONDITIONS
Kline, N. S. (1954) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1954.tb45922.x · Cited by 193
Dracheva, S., Marras, S. A. E., Elhakem, S. L., Kramer, F. R., Davis, K. L., & Haroutunian, V. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1400 · Cited by 190
Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation
Lü, W., Du, J., Goehring, A., & Gouaux, E. (2017) · Science · doi:10.1126/science.aal3729 · Cited by 176
Genetic variation in DTNBP1 influences general cognitive ability
Burdick, K. E., Lencz, T., Funke, B., Finn, C. T., Szeszko, P. R., Kane, J. M., Kucherlapati, R., & Malhotra, A. K. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi481 · Cited by 173
TSPO in diverse CNS pathologies and psychiatric disease: a critical review and a way forward
Guilarte, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.003 · Cited by 173
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Catts, V. S., Lai, Y. L., Weickert, C. S., Weickert, T. W., & Catts, S. V. (2015) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.013 · Cited by 169
Conus, P., Seidman, L. J., Fournier, M., Xin, L., Cleusix, M., Baumann, P. S., Ferrari, C., Cousins, A., Alameda, L., Gholam-Rezaee, M., et al. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx093 · Cited by 162
Benneyworth, M. A., Li, Y., Basu, A. C., Bolshakov, V. Y., & Coyle, J. T. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9808-4 · Cited by 159
Self-citationGlutamatergic abnormalities in schizophrenia: A review of proton MRS findings
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.013 · Cited by 158
Farokhnia, M., Azarkolah, A., Adinehfar, F., Khodaie-Ardakani, M.-R., Hosseini, S.-M.-R., Yekehtaz, H., Tabrizi, M., Rezaei, F., Salehi, B., Sadeghi, S.-M.-H., et al. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000001 · Cited by 155
Johnstone, E. C., Owens, D. G. C., Bydder, G. M., Colter, N., Crow, T. J., & Frith, C. (1989) · Psychological Medicine · doi:10.1017/s0033291700011053 · Cited by 155
Yang, J. H., Wada, A., Yoshida, K., Miyoshi, Y., Sayano, T., Esaki, K., Kinoshita, M. O., Tomonaga, S., Azuma, N., Watanabe, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.187443 · Cited by 153
The Effects of a Sub-Anaesthetic Dose of Ketamine on Human Selective Attention
Oranje, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00118-9 · Cited by 147
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144
Javitt, D. C., Duncan, L., Balla, A., & Sershen, H. W. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001552 · Cited by 138
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
Maksymetz, J., Moran, S. P., & Conn, P. J. (2017) · Molecular Brain · doi:10.1186/s13041-017-0293-z · Cited by 138
Rook, J. M., Xiang, Z., Lv, X., Ghoshal, A., Dickerson, J. W., Bridges, T. M., Johnson, K. A., Foster, D. J., Gregory, K. J., Vinson, P. N., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.063 · Cited by 136
Husi, H., & Grant, S. G. N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00248.x · Cited by 136
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., & Lenaerts, F. M. (1967) · PubMed · Cited by 134
Gray, L., van den Buuse, M., Scarr, E., Dean, B., & Hannan, A. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009085 · Cited by 130
d-Serine and Serine Racemase are Localized to Neurons in the Adult Mouse and Human Forebrain
Balu, D. T., Takagi, S., Puhl, M. D., Benneyworth, M. A., & Coyle, J. T. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0027-z · Cited by 130
Self-citationHigh-resolution copy number variation analysis of schizophrenia in Japan
Kushima, I., Aleksić, B., Nakatochi, M., Shimamura, T., Shiino, T., Yoshimi, A., Kimura, H., Takasaki, Y., Wang, C., Xing, J., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.88 · Cited by 130
Self-citationJana, A., Modi, K. K., Roy, A., Anderson, J. A. D., van Breemen, R. B., & Pahan, K. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9447-7 · Cited by 128
Janssen, P. A., Cj, N., & Schellekens, K. H. L. (1966) · PubMed · Cited by 127
Enhanced astrocytic d-serine underlies synaptic damage after traumatic brain injury
Perez, E. J., Tapanes, S. A., Loris, Z. B., Balu, D. T., Sick, T. J., Coyle, J. T., & Liebl, D. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92300 · Cited by 127
Self-citationTakahashi, H., Rissling, A. J., Pascual-Marqui, R. D., Kirihara, K., Pela, M., Sprock, J., BRAFF, D. L., & Light, G. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.074 · Cited by 122
Refining the psychiatric syndrome of anti‐N‐methyl‐ d ‐aspartate receptor encephalitis
Warren, N., Siskind, D. J., & O’Gorman, C. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12941 · Cited by 121
D-serine in glia and neurons derives from 3-phosphoglycerate dehydrogenase
Ehmsen, J. T., Ma, T. M., Sason, H., Rosenberg, D., Ogo, T., Furuya, S., Snyder, S. H., & Wolosker, H. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4914-12.2013 · Cited by 118
Targeting of NMDA receptors in new treatments for schizophrenia
Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 117
TREATMENT OF SCHIZOPHRENIC REACTIONS WITH PHENOTHIAZINE DERIVATIVES
Casey, J. F., Lasky, J. J., Klett, C. J., & Hollister, L. E. (1960) · American Journal of Psychiatry · doi:10.1176/ajp.117.2.97 · Cited by 115
Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia
Ohnuma, T., Kato, H., Arai, H., Faull, R. L. M., McKenna, P. J., & Emson, P. C. (2000) · Neuroreport · doi:10.1097/00001756-200009280-00019 · Cited by 115
Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology
DeVito, L. M., Balu, D. T., Kanter, B. R., Lykken, C., Basu, A. C., COYLE, J. T., & Eichenbaum, H. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00656.x · Cited by 114
Self-citationA Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia
Morita, Y., Ujike, H., Tanaka, Y., Otani, K., Kishimoto, M., Morio, A., Kotaka, T., Okahisa, Y., Matsushita, M., Morikawa, A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.025 · Cited by 113
d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
Evins, A. E., Amico, E. T., Posever, T. A., Toker, R., & GOFF, D. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00220-1 · Cited by 111
A decade in psychiatric GWAS research
Horwitz, T. B., Lam, K., Chen, Y., Xia, Y., & Liu, C. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0055-z · Cited by 109
Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation
Wood, S. J., Berger, G. E., Wellard, R. M., Proffitt, T., McConchie, M., Berk, M., McGorry, P. D., & Pantelis, C. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.018 · Cited by 107
Holcomb, H. H., Lahti, A. C., Medoff, D. R., Cullen, T. J., & Tamminga, C. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300824 · Cited by 106
Yao, Y., Belcher, J., Berger, A. J., Mayer, M. L., & Lau, A. Y. (2013) · Structure · doi:10.1016/j.str.2013.07.011 · Cited by 105
Nagai, T., Tada, M., Kirihara, K., Yahata, N., Hashimoto, R., Araki, T., & Kasai, K. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.005 · Cited by 105
DISTRIBUTION OF d ‐AMINO ACID OXIDASE IN BOVINE AND HUMAN NERVOUS TISSUES*
Neims, A. H., Zieverink, W. D., & Smilack, J. D. (1966) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1966.tb07508.x · Cited by 104
Bugarski‐Kirola, D., Wang, A., Abi‐Saab, D., & Blaettler, T. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.007 · Cited by 103
Astroglial versus Neuronal D-Serine: Fact Checking
Papouin, T., Henneberger, C., Rusakov, D. A., & Oliet, S. H. R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.05.007 · Cited by 103
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Hovelsø, N., Sotty, F., Montezinho, L. P., Pinheiro, P. S., Herrik, K. F., & Mørk, A. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362805 · Cited by 101
Terpstra, M., Vaughan, T. J., Uǧurbil, K., Lim, K. O., Schulz, S. C., & Rolf Gruetter, A. (2005) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-005-0012-0 · Cited by 98
Sepehrmanesh, Z., Heidary, M., Akasheh, N., Akbari, H., & Heidary, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.001 · Cited by 98
Schwieler, L., Linderholm, K. R., Nilsson-Todd, L. K., Erhardt, S., & Engberg, G. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.05.014 · Cited by 97
Yui, K., Ikemoto, S., Ishiguro, T., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05178.x · Cited by 96
Mismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals
Näätänen, R., Todd, J., & Schall, U. (2015) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.010 · Cited by 95
Iwata, Y., Nakajima, S., Suzuki, T., Keefe, R. S. E., Plitman, E., Chung, J. K., Caravaggio, F., Mimura, M., Graff‐Guerrero, A., & Uchida, H. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.68 · Cited by 93
Litman, R. E., Smith, M. A., Doherty, J., Cross, A. J., Raines, S. R., Gertsik, L., & Zukin, S. R. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.001 · Cited by 93
Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in micePreprint
Labrie, V., Duffy, S. N., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. (2008) · Learning & Memory · doi:10.1101/lm.1112209 · Cited by 90
Zheng, W., Zhang, Q. ‐., Cai, D., Yang, X.-H., Qiu, Y., Ungvari, G. S., Ng, C. H., Berk, M., Ning, Y., & Xiang, Y. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12862 · Cited by 88
Wolosker, H., & Radzishevsky, I. S. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130220 · Cited by 87
Li, Y., Sacchi, S., Pollegioni, L., Basu, A. C., Coyle, J. T., & Bolshakov, V. Y. (2013) · Nature Communications · doi:10.1038/ncomms2779 · Cited by 82
Self-citationMa, J., & Leung, L.-W. S. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00138-8 · Cited by 82
Efficacy of Tranquilizing and Antidepressant Drugs
Davis, J. M. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01730060070010 · Cited by 77
Zavitsanou, K., Ward, P. B., & Huang, X. F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00347-0 · Cited by 76
d-Cycloserine augmentation of cognitive remediation in schizophrenia
Cain, C. K., McCue, M. G., Bello, I., Creedon, T. B., Tang, D., LASKA, E. M., & GOFF, D. C. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.016 · Cited by 75
Girgis, R. R., Phillips, M. R., Li, X., Li, K., Jiang, H., Wu, C., Duan, N., Niu, Y., & Lieberman, J. A. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.081471 · Cited by 73
Behavioral changes in G72/G30 transgenic mice
Otte, D. M., Bilkei‐Gorzó, A., Filiou, M. D., Turck, C. W., Yilmaz, Ö., Holst, M. I., Schilling, K., Jamra, R. A., Schumacher, J., Benzel, I. M., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.009 · Cited by 72
The phencyclidine psychosis: phenomenology and treatment.
Luisada, P. V. (1978) · PubMed · Cited by 67
Banerjee, A., Wang, H.-Y., Borgmann‐Winter, K. E., MacDonald, M. L., Kaprielian, H., Stucky, A., Kvasic, J., Egbujo, C. N., Ray, R., Talbot, K., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.115 · Cited by 65
LAWLOR, B. A., & Davis, K. L. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90227-q · Cited by 63
Nagai, T., Kirihara, K., Tada, M., Koshiyama, D., Koike, S., Suga, M., Araki, T., Hashimoto, K., & Kasai, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02267-1 · Cited by 62
Harada, K., Nakato, K., Yarimizu, J., Yamazaki, M., Morita, M., Takahashi, S., Aota, M., Saita, K., Doihara, H., Sato, Y. Z., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.013 · Cited by 60
Balu, D. T., Li, Y., Takagi, S., Presti, K. T., Ramikie, T. S., Rook, J. M., Jones, C. K., Lindsley, C. W., Conn, P. J., Bolshakov, V. Y., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.2 · Cited by 60
Self-citationYu, Y., Lin, Y., Takasaki, Y., Wang, C., Kimura, H., Xing, J., Ishizuka, K., Toyama, M., Kushima, I., Mori, D., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0061-y · Cited by 59
Self-citationThe Role of Serine Racemase in the Pathophysiology of Brain Disorders
Coyle, J. T., & Balu, D. T. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.10.002 · Cited by 58
Self-citationLi, S., Uno, Y., Rudolph, U., Cobb, J., Liu, J., Anderson, T., Levy, D. L., Balu, D. T., & Coyle, J. T. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.023 · Cited by 56
Self-citationKishi, T., Matsuda, Y., & Iwata, N. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4616-7 · Cited by 55
Vrajová, M., Šťastný, F., Horáček, J., Lochman, J., Šerý, O., Peková, Š., Klaschka, J., & Höschl, C. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0145-z · Cited by 54
Toward Illness Phase–Specific Pharmacotherapy for Schizophrenia
Krystal, J. H., & Anticevic, A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.017 · Cited by 53
The relationship between negative symptom subdomains and cognition
Lim, J., Lee, S.-A., Lam, M., Rapisarda, A., Kraus, M., Keefe, R. S. E., & Lee, J. (2016) · Psychological Medicine · doi:10.1017/s0033291716000726 · Cited by 53
History of the Concept of Disconnectivity in Schizophrenia
Coyle, J. T., Balu, D. T., Puhl, M. D., & Konopaske, G. T. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000102 · Cited by 51
Self-citationNAAG, NMDA Receptor and Psychosis
Bergeron, R., & Coyle, J. T. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799462685 · Cited by 50
Self-citationElectrophysiological signs of reduced prefrontal response control in schizophrenic patients
Fallgatter, A. J., & Müller, T. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00092-0 · Cited by 50
Glycine transporter inhibition reverses ketamine-induced working memory deficits
Roberts, B. M., Shaffer, C. L., Seymour, P. A., Schmidt, C. J., Williams, G. V., & Castner, S. A. (2010) · Neuroreport · doi:10.1097/wnr.0b013e3283381a4e · Cited by 50
Rossell, S. L., Francis, P. S., Galletly, C. A., Harris, A. W. F., Siskind, D. J., Berk, M., Bozaoglu, K., Dark, F. L., Dean, O. M., Liu, D., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1030-3 · Cited by 50
D’Souza, D. C., Carson, R. E., Driesen, N. R., Johannesen, J., Ranganathan, M., Krystal, J. H., Ahn, K.-H., Forselius-Bielen, K., Carbuto, M., Deaso, E., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.019 · Cited by 50
Kim, S.-Y., Kaufman, M. J., Cohen, B. M., Jensen, J. E., Coyle, J. T., Du, F., & Öngür, D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.022 · Cited by 47
Self-citationSchoemaker, J. H., Jansen, W. T., Schipper, J., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000073 · Cited by 45
Clozapine Augmented with Glutamate Modulators in Refractory Schizophrenia: A Review and Metaanalysis
Veerman, S. R. T., Schulte, P. F. J., Begemann, M., Engelsbel, F., & de Haan, L. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1383656 · Cited by 43
A Half-Century of Neurotransmitter Research: Impact on Neurology and Psychiatry (Nobel Lecture)
Carlsson, A. (2001) · ChemBioChem · doi:10.1002/1439-7633(20010803)2:7/8<484::aid-cbic484>3.0.co;2-5 · Cited by 42
D-Serine and Glycine Differentially Control Neurotransmission during Visual Cortex Critical Period
Meunier, C. N. J., Dallérac, G. M., Roux, N. L., Sacchi, S., Levasseur, G., Amar, M., Pollegioni, L., Mothet, J., & Fossier, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151233 · Cited by 42
Efficacy of Memantine in Schizophrenic Patients: A Systematic Review
Iorio, G. D., Baroni, G., Lorusso, M., Montemitro, C., Spano, M. C., & Giannantonio, M. D. (2017) · Journal of Amino Acids · doi:10.1155/2017/7021071 · Cited by 41
Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Singer, P., Dubroqua, S., & Yee, B. K. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150724100952 · Cited by 39
Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia
Ghose, S., Chin, R., Gallegos, A., Roberts, R. C., Coyle, J. T., & Tamminga, C. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.038 · Cited by 39
Self-citationFrontal P3 event-related potential is related to brain glutamine/glutamate ratio measured in vivo
Hall, M., Jensen, J. E., Du, F., Smoller, J. W., O’Connor, L., Spencer, K., & Öngür, D. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.02.014 · Cited by 37
Kimura, H., Fujita, Y., Kawabata, T., Ishizuka, K., Wang, C., Iwayama, Y., Okahisa, Y., Kushima, I., Morikawa, M., Uno, Y., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.170 · Cited by 30
Self-citationKleinlogel, H., Strik, W. K., & Begré, S. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.08.022 · Cited by 22
The Therapeutic Role of d-Cycloserine in Schizophrenia
GOFF, D. C. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.02.001 · Cited by 19
Is schizophrenia disappearing? The rise and fall of the diagnosis of functional psychoses: an essay
Bergsholm, P. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1101-5 · Cited by 18
Sturm, S., Delporte, M., Hadi, S., Schobel, S., Lindemann, L., Weikert, R. J., Jaeschke, G., Derks, M., & Palermo, G. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13466 · Cited by 14
GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia
Geddes, A. E., Huang, X., & Newell, K. A. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0274-z · Cited by 11
Biological research on schizophrenia
Toru, M. (1998) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1998.tb03213.x · Cited by 10
Cited by
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Neural Circuitry of Salience and Reward Processing in Psychosis
Kesby, J. P., Murray, G. K., & Knolle, F. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.12.003 · Cited by 55
de Boer, J. N., Vingerhoets, C., Hirdes, M., McAlonan, G. M., Amelsvoort, T. V., & Zinkstok, J. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.06.020 · Cited by 38
Leithead, A. B., Tasker, J. G., & Harony‐Nicolas, H. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13061 · Cited by 26
Metadata
- Authors
- Uno, Y., & Coyle, J. T.
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2019-03-06
- Volume
- 73
- Issue
- 5
- Pages
- 204-215
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W2913588197
- Cited by
- 367
- References
- 190
- FWCI
- 30.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.